AstraZeneca plc (LON: AZN) recently received a number of ratings updates from brokerages and research firms:

  • 9/25/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/25/2017 – AstraZeneca plc was given a new GBX 5,800 ($76.93) price target on by analysts at BNP Paribas. They now have a “buy” rating on the stock.
  • 9/25/2017 – AstraZeneca plc was given a new GBX 5,780 ($76.67) price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 9/25/2017 – AstraZeneca plc had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 6,300 ($83.57) price target on the stock.
  • 9/21/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Societe Generale.
  • 9/19/2017 – AstraZeneca plc was given a new GBX 5,800 ($76.93) price target on by analysts at Berenberg Bank. They now have a “buy” rating on the stock.
  • 9/18/2017 – AstraZeneca plc was given a new GBX 4,900 ($65.00) price target on by analysts at Jefferies Group LLC. They now have a “neutral” rating on the stock.
  • 9/14/2017 – AstraZeneca plc was downgraded by analysts at Liberum Capital from a “buy” rating to a “hold” rating. They now have a GBX 5,000 ($66.32) price target on the stock, up previously from GBX 4,800 ($63.67).
  • 9/14/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 4,500 ($59.69) price target on the stock.
  • 9/13/2017 – AstraZeneca plc was given a new GBX 6,300 ($83.57) price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 9/13/2017 – AstraZeneca plc was given a new GBX 6,000 ($79.59) price target on by analysts at Citigroup Inc.. They now have a “buy” rating on the stock.
  • 9/11/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Kepler Capital Markets. They now have a GBX 5,200 ($68.97) price target on the stock.
  • 9/11/2017 – AstraZeneca plc was upgraded by analysts at Bryan, Garnier & Co to a “buy” rating. They now have a GBX 5,380 ($71.36) price target on the stock, up previously from GBX 4,700 ($62.34).
  • 9/11/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 9/11/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at Credit Suisse Group. They now have a GBX 4,700 ($62.34) price target on the stock.
  • 9/11/2017 – AstraZeneca plc was given a new GBX 5,300 ($70.30) price target on by analysts at BNP Paribas. They now have a “neutral” rating on the stock.
  • 9/11/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Berenberg Bank. They now have a GBX 5,500 ($72.95) price target on the stock.
  • 9/11/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 4,800 ($63.67) price target on the stock.
  • 9/11/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Societe Generale.
  • 9/11/2017 – AstraZeneca plc had its price target raised by analysts at Jefferies Group LLC from GBX 4,350 ($57.70) to GBX 4,800 ($63.67). They now have a “hold” rating on the stock.
  • 9/11/2017 – AstraZeneca plc had its price target raised by analysts at Deutsche Bank AG from GBX 5,300 ($70.30) to GBX 5,600 ($74.28). They now have a “buy” rating on the stock.
  • 9/11/2017 – AstraZeneca plc had its “reduce” rating reaffirmed by analysts at HSBC Holdings plc. They now have a GBX 4,100 ($54.38) price target on the stock.
  • 9/11/2017 – AstraZeneca plc had its “sell” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a GBX 3,800 ($50.40) price target on the stock.
  • 9/11/2017 – AstraZeneca plc was given a new GBX 4,550 ($60.35) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 9/8/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 4,200 ($55.71) price target on the stock.
  • 9/7/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Citigroup Inc..
  • 9/6/2017 – AstraZeneca plc was upgraded by analysts at Natixis from a “neutral” rating to a “buy” rating. They now have a GBX 5,738 ($76.11) price target on the stock, up previously from GBX 5,000 ($66.32).
  • 9/5/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 4,800 ($63.67) price target on the stock.
  • 9/5/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 5,300 ($70.30) price target on the stock.
  • 9/1/2017 – AstraZeneca plc had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a GBX 4,200 ($55.71) price target on the stock.
  • 8/31/2017 – AstraZeneca plc was given a new GBX 4,550 ($60.35) price target on by analysts at UBS AG. They now have a “neutral” rating on the stock.
  • 8/30/2017 – AstraZeneca plc had its price target lowered by analysts at Goldman Sachs Group, Inc. (The) from GBX 3,900 ($51.73) to GBX 3,800 ($50.40). They now have a “sell” rating on the stock.
  • 8/29/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/24/2017 – AstraZeneca plc had its price target lowered by analysts at Jefferies Group LLC from GBX 4,400 ($58.36) to GBX 4,350 ($57.70). They now have a “hold” rating on the stock.
  • 8/21/2017 – AstraZeneca plc had its “buy” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 4,800 ($63.67) price target on the stock.
  • 8/18/2017 – AstraZeneca plc had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 8/18/2017 – AstraZeneca plc was given a new GBX 3,900 ($51.73) price target on by analysts at Goldman Sachs Group, Inc. (The). They now have a “sell” rating on the stock.
  • 8/9/2017 – AstraZeneca plc was upgraded by analysts at Investec from a “hold” rating to a “buy” rating. They now have a GBX 4,900 ($65.00) price target on the stock, down previously from GBX 5,000 ($66.32).
  • 8/9/2017 – AstraZeneca plc was given a new GBX 4,200 ($55.71) price target on by analysts at J P Morgan Chase & Co. They now have a “neutral” rating on the stock.
  • 8/8/2017 – AstraZeneca plc was given a new GBX 4,100 ($54.38) price target on by analysts at HSBC Holdings plc. They now have a “sell” rating on the stock.
  • 8/7/2017 – AstraZeneca plc had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 5,500 ($72.95) price target on the stock.

Shares of AstraZeneca plc (LON AZN) opened at 5069.00 on Wednesday. The company’s market cap is GBX 64.17 billion. The company’s 50-day moving average is GBX 4,692.03 and its 200 day moving average is GBX 4,893.11. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.

The firm also recently disclosed a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were paid a GBX 68.90 ($0.91) dividend. The ex-dividend date was Thursday, August 10th. This represents a yield of 1.35%.

In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($57.97) per share, for a total transaction of £1,704.30 ($2,260.64).

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.